Express Pharma
Home  »  Pharma Ally  »  Chiltern ranks among top CROs in global survey of clinical research sites

Chiltern ranks among top CROs in global survey of clinical research sites

19

The CenterWatch survey conducted between October 2014 and January 2015 measured 38 attributes of CRO-site relations from study planning to innovation

Chiltern, a leading global CRO, has ranked third among all CROs in the 2015 CenterWatch survey of 1,900 global investigative sites. The CenterWatch survey conducted between October 2014 and January 2015 measured 38 attributes of CRO-site relations from study planning to innovation. Respondents from investigators and study coordinators, 75 per cent of them from North America and Europe, rated Chiltern in the top three for 27 of those attributes. The 2015 survey demonstrates marked improvement for CRO effectiveness overall compared the prior survey two years ago.

On Chiltern’s high ranking, Susan Romberg, Vice President, Global Clinical Development noted, “Chiltern sees the benefits of specialisation through having a deep understanding of the patient experience and appreciation for challenging site logistics. This is why we invest in building strong partnerships with site coordinators and investigators.”

Romberg went on to note the impact of internal efforts also: “Chiltern’s transparent culture, career development planning for both technical and soft skills, empowered leadership at all levels and a positive, supportive work environment all contribute to employee retention that exceeds industry averages for improved site relations.”

“We’ve seen growing value in relationship-building among all parties in the clinical development process and site alliances are a significant part of that,” commented Chiltern Chief Operating Officer, Aize Smink. “I’m proud of our teams for this recognition to make site relationships a core focus, we could not be successful without the support of all our investigators and their staff globally.”

EP News BureauMumbai

Comments are closed.